Effect of the adenovirus-mediated monocyte chemoattrarctant protein-one (MCP-1) gene and NK4 gene co-expression in pancreatic cancer cell

doi:10.3877/cma.j.issn.1647-0793.2013.03.001

Abstract

Abstract:

Objective

To investigate the effect of the adenovirus-mediated NK4 and MCP-1 gene co-expression in pancreatic cancer cell in vitro.

Methods

NK4 gene and MCP-1 gene were singly and conjointly transfected into pancreatic cancer cells SW1990 by adenovirus vector. The expressions of NK4 and MCP-1 were detected using RT-PCR and ELISA. Then the influence on the growth of pancreatic cancer cells and vascular endothelial cells were observed.

Results

When MOI was 60 efu/cell, the infection efficiency of SW1990 was 100%. The expression of MCP-1 and NK4 mRNA were the highest in the 5th days in all the three groups. The expressions of MCP-1 and NK4 in conjoint group were lower than either single MCP-1 or single NK4 group. There was no significant difference in the growth curve of all the three and control groups. Both AD-NK4 and conjoint groups can inhibit the growth of vascular endothelial cells, but no significant difference was found between the two groups.

Conclusions

Adenovirus-mediated NK4 and MCP-1 genes can effectively infect SW1990, and did not show inhibiting effect in vitro. However, NK4 may play the role of tumor suppressor through inhibiting tumor angiogenesis.

Key words: Pancreatic neoplasms, Heptatocyte growth factor, Monocyte chemoattractant protein 1, Genetic therapy, Adenovirus

Hua-ping ZHOU, He-ping PENG, Qi-cai LIU. Effect of the adenovirus-mediated monocyte chemoattrarctant protein-one (MCP-1) gene and NK4 gene co-expression in pancreatic cancer cell[J]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(03): 165-169.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1647-0793.2013.03.001

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2013/V07/I03/165

Figures/Tables 3

References 11

1	Date K, Matsumoto K, Shimura H, et al. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett, 1997, 420(1): 1-6.
2	Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci, 2003, 94(4): 321-327.
3	Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol, 2004, 14(3): 149-154.
4	Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control, 2000, 7(5): 421-427.
5	王琳，郭永章，李立, 等. 单纯疱疹病毒Ⅱ型胸苷激酶基因对人原发性肝细胞癌治疗作用的实验研究. 中华肝胆外科杂志, 2003, 9(5): 306-308.
6	Drozdzik M, Qian C, Xie X, et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol, 2000, 32(2): 279-286.
7	Otte JM, Kiehne K, Schmitz F, et al. C-Met protooncogene expression and its regulation by cytokines in the regenerating pancreas and in pancreatic cancer cells. Scand J Gastroenterol, 2000, 35(1): 90-95.
8	Kushibiki T, Matsumoto K, Nakamura T, et al. Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres. Pharm Res, 21(7): 1109-1118.
9	Murakami M, Nagai E, Mizumoto K, et al. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer, 2005, 117(1): 160-165.
10	Saimura M, Nagai E, Mizumoto K, et al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res, 2002, 8(10): 3243-3249.
11	Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res, 2003, 63(21): 7451-7461.

[1]	Zhongzheng Ma, Yunchuan Yang, Xiang Ma, Chi Zhou, Ding Ding, Junyi Huo, Nan Xu, Peiyuan Cui, Lei Zhou. Construction of a disulfidptosis-related lncRNA prognostic model for pancreatic cancer and study of immune response [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 368-376.
[2]	Wenbin Luo, Wei Han. Analysis of risk factors related to moderate to severe myelosuppression in patients with pancreatic cancer after first chemotherapy and construction of prediction model [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 357-362.
[3]	Chengwang Fu, Dagang Yang, Rong Wang, Futang Li. Research progress of nutritional and inflammatory markers in resectable pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 704-708.
[4]	Jiang Zhu, Jin Zhang, YunFei Kong, Jun Li, Xu Song. The relationship between Fusobacterium nucleatum and pancreatic cancer and its clinical significance [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 448-451.
[5]	Chengyu Shi, Xiaolin Ji, Liying Tian, Laixiang Zhang. Clinical effect of 14c/d group lymph node dissection during laparoscopic pancreaticoduodenectomy in patients with pancreatic head cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 430-433.
[6]	Ti Zhou, Jia Wu, Fang Han, Linwei Xu, Yuhua Zhang. Research progress in lymph node dissection for pancreatic cancer in the era of neoadjuvant therapy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 634-639.
[7]	Hao Zhang, Weidong Pan. Current status and progress in assessment of resectability of pancreatic cancer after neoadjuvant chemotherapy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 629-633.
[8]	Shixiang Guo, Mingda Tan, Huaizhi Wang. Rethinking lymph node dissection in pancreatic head cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 625-628.
[9]	Junhua Wang, Ruixuan Wang. Current status and treatment strategy of neoadjuvant chemotherapy for pancreatic cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 640-643.
[10]	Miaoyan Wei, Jin Xu. Progress and prospects of systemic treatment for pancreatic cancer with distant metastasis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 644-650.
[11]	Liuping Luo, Mengmeng Wu, Xinlei Chen, Kecan Lin. Application value of total mesopancreas excision in radical resection of pancreatic head cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 651-656.
[12]	Yu Zhang, Mengni Jiang. Establishment of prediction model for survival benefits of locally advanced pancreatic cancer patients after radiochemotherapy based on DWI signal value [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 657-664.
[13]	Xiujun Yang, Mengying Cui, Shui Liu, Jiyao Sheng, Dan Zhang. Construction and validation of prognostic nomogram for patients with pancreatic neuroendocrine carcinoma on the head of pancreas based on SEER database [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 520-525.
[14]	Yongyang Wei, Junfu Huang, Wanpeng Xin, Siqing Yi, Shuju Tu, Kang Fang, Yong Li, Weidong Xiao. Clinical efficacy of three surgical treatments for benign or low-grade malignant tumors in the neck and body of pancreas [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 515-519.
[15]	Yan Liao, Wei Cheng. Application of laparoscopy in pancreatic cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 259-264.

Please choose a citation manager

Content to export